Skip to main content
ONO PHARMACEUTICAL CO., LTD. logo

ONO PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 4528 ISIN · JP3197600004 LEI · 529900G26L4NG4GFJZ86 T Manufacturing
Open in API
Filings indexed 65 across all filing types
Latest filing 2025-11-06 Regulatory Filings
Country JP Japan
Listing T 4528

About ONO PHARMACEUTICAL CO., LTD.

https://www.ono-pharma.com/en

Ono Pharmaceutical Co., Ltd. is a research and development-oriented pharmaceutical company dedicated to discovering and developing innovative medicines. With a history spanning over 300 years since its founding in 1717, the company focuses on addressing unmet medical needs for patients worldwide. Its primary research and development areas are oncology, immunology, and neurology. Ono Pharmaceutical is committed to creating unique, first-in-class drugs and is particularly recognized for its pioneering work in the field of immuno-oncology. The company's portfolio consists of prescription pharmaceuticals aimed at treating a range of diseases and conditions.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification by the CEO of Ono Pharmaceutical Co., Ltd., confirming the accuracy of the contents of the semi-annual report for the period ending September 30, 2025. Per the 'Certification Rule', documents that are primarily officer certifications or attestations, even if they reference a specific report type, should be classified as Regulatory Filings (RNS) rather than the report itself. H1 78
2025-11-06 Japanese
半期報告書－第78期(2025/04/01－2026/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed by Ono Pharmaceutical Co., Ltd. with the Kanto Local Finance Bureau on November 6, 2025. It covers the interim accounting period from April 1, 2025, to September 30, 2025. It contains detailed financial statements, management analysis (MDA), and operational updates, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2026
2025-11-06 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is extremely short (678 characters) and contains a header structure typical of Japanese regulatory filings, specifically mentioning '【提出書類】 確認書' (Filing Document: Confirmation Document) and referencing the Financial Instruments and Exchange Act ('金融商品取引法'). The core content confirms that the Representative Director has verified the appropriateness of the contents of the '有価証券報告書の訂正報告書' (Correction Report for the Annual Securities Report) for the fiscal year ending March 31, 2025. Since this document is a short confirmation/attestation regarding the accuracy of a previously filed report (likely a 10-K correction), and not the full report itself, it fits best under the general 'Regulatory Filings' category (RNS) as a specific confirmation document that doesn't match other detailed categories like ER, IR, or 10-K. It is not an announcement of a report publication (RPA) but a specific regulatory confirmation filing. FY 2025
2025-07-01 Japanese
訂正有価証券報告書－第77期(2024/04/01－2025/03/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yukashoken Hokokusho' (Annual Securities Report), which is the Japanese equivalent of a 10-K. The header explicitly identifies it as an 'Annual Securities Report' (有価証券報告書) and includes a fiscal year period (2024-04-01 to 2025-03-31). It contains XBRL data and detailed financial disclosures, confirming it is the full annual report rather than an announcement or summary. FY 2025
2025-07-01 Japanese
臨時報告書
AGM Information Classification · 100% confidence The document is titled '臨時報告書' (Extraordinary Report) and explicitly states in Section 1 that it is being submitted based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and related Cabinet Office Ordinance, following the resolutions passed at the 77th Annual General Meeting (定時株主総会) held on June 19, 2025. The content details the resolutions, including dividend approval and director elections, along with the voting results (votes for, against, abstentions). This structure perfectly matches the definition of reporting the results of a shareholder meeting vote, which corresponds to the Declaration of Voting Results & Voting Rights Announcements (DVA). Although it relates to the AGM, the primary function is reporting the *results* of the vote, not providing the AGM presentation materials (AGM-R).
2025-06-20 Japanese
臨時報告書
Share Issue/Capital Change Classification · 100% confidence The document is titled with headers indicating it is a '臨時報告書' (Extraordinary Report or Timely Disclosure Report) submitted to the '関東財務局長' (Kanto Local Finance Bureau Director) on June 19, 2025. Section 1 explicitly states the reason for filing: to report the resolution (本付与決議) made by the Board of Directors regarding the grant of stock compensation units (本ユニット) to directors and executive officers under the performance-linked restricted stock plan, citing Article 24-5(4) of the Financial Instruments and Exchange Act. This structure—a formal report detailing a specific corporate action (like stock issuance or compensation) required by securities law—is characteristic of a timely disclosure filing in Japan. Since the content details the issuance/grant of shares (228,300 shares) as compensation, it relates to capital structure changes or insider transactions, but the primary nature is the formal disclosure of a board resolution concerning executive compensation/share issuance. Given the options, this is a mandatory regulatory filing that doesn't fit perfectly into specific categories like 10-K, ER, or DIV. The closest fit for a mandatory, non-periodic, specific corporate action disclosure that isn't a standard annual/quarterly report is the general 'Regulatory Filings' (RNS) or potentially 'Capital/Financing Update' (CAP) due to the share issuance aspect. However, the document format (a formal Japanese '臨時報告書' filing) strongly suggests a general regulatory disclosure. Since the document is comprehensive and not just an announcement *about* a report (ruling 2 does not apply), and it details a specific corporate action (stock compensation grant), RNS is the most appropriate fallback for a specific, non-standard regulatory filing not covered by other codes.
2025-06-19 Japanese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.